{
  "id": 12364134,
  "title": "Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update",
  "url": "https://urgent.news/2026/10/06/marvel-biosciences-signs-letter-of-intent-with-novatech-for-phase-1",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-06T10:48:15.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/marvel-biosciences-signs-letter-of-intent-with-novatech-for-phase-1-trial-of-mb-204-and-provides-corporate-update"
  },
  "original_language": "en",
  "account": null,
  "summary": "CALGARY, Alberta, Oct. 06, 2026 (GLOBE NEWSWIRE) — Marvel Biosciences Corp. (TSXV: MRVL | OTCQB: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), a drug discovery company developing novel therapeutics for autism spectrum disorder (“ASD”) and related neurodevelopmental disorders, is pleased to announce it has signed a letter of intent…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Nasdaq Markets",
        "title": "Marvel To Move Forward Into Phase I Trial For MB-204 In Partnership With Novatech",
        "url": "https://urgent.news/2026/10/06/marvel-to-move-forward-into-phase-i-trial-for-mb-204-in-partnership",
        "published": "2026-10-06T11:24:42.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}